Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

elbasvir / grazoprevir

Known as: ELBASVIR/GRAZOPREVIR, elbasvir and grazoprevir 
 
National Institutes of Health

Related topics

Related topics

2 relations
elbasvirgrazoprevir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir.
Doravirine is a non-nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus type 1 (HIV-1… Expand
Is this relevant?
2019
2019
Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b
AIM Treatment with all-oral direct-acting antiviral agents (DAAs) elbasvir/grazoprevir (EBR/GZR) is associated with high… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2019
2019
Retreatment with Elbasvir, Grazoprevir, Sofosbuvir +/- Ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.
INTRODUCTION Despite highly effective direct-acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection, some… Expand
Is this relevant?
2019
2019
Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir
BACKGROUND Elbasvir/grazoprevir is a once-daily fixed-dose combination therapy for the treatment of chronic HCV infection… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2019
2019
Direct acting anti-viral medications for hepatitis C: Clinical trials in patients with advanced chronic kidney disease.
Hepatitis C is a global health concern, with important implications in chronic kidney disease (CKD) due to its increased… Expand
Is this relevant?
2018
2018
Cost-Effectiveness of Elbasvir/Grazoprevir Versus Daclatasvir Plus Asunaprevir in Patients with Chronic Hepatitis C Virus Genotype 1b Infection in China
Background and ObjectiveNew direct-acting antivirals (DAAs) have high efficacy and tolerability in the treatment of hepatitis C… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2017
2017
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
BACKGROUND & AIMS Persons with hepatitis C virus (HCV) infection are at risk of progressive liver disease, cirrhosis, and… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
2017
2017
Cost‐effectiveness of elbasvir/grazoprevir use in treatment‐naive and treatment‐experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States
Among patients with chronic kidney disease (CKD) in the United States, HCV infection causes significant morbidity and mortality… Expand
Is this relevant?
2016
2016
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial.
BACKGROUND & AIMS Direct-acting antiviral agents have improved treatment outcomes for patients with hepatitis C virus (HCV… Expand
  • table 1
  • table 2
  • table 3
Is this relevant?
2016
2016
Hepatitis C in Pregnancy: Screening and Current Treatments
Hepatitis C virus (HCV) infection affects around 170 million men and women all over the world. Many patients with chronic HCV… Expand
  • table 1
  • table 2
  • table 3
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE